24 Mar, 2021
Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing
17 Mar, 2021
SHANGHAI, China, March 17, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that the Company has submitted a clinical trial application to the Bellberry Human Research Ethics Committee in Australia for First In Human (FIH) clinical trial of GB261, a novel CD20/CD3 bispecific antibody, in patients with B-cell non-Hodgkin Lymphoma (B-NHL).
15 Mar, 2021
SHANGHAI, China, March 15, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that Genor Biopharma was officially included into the Heng Seng Composite Index (HSCI). This was announced by Hang Seng Index Limited according to the results of its review of the Heng Seng Family of Indexes for the quarter ended 31 December 2020, and has been effective since March 15, 2021.
12 Mar, 2021
SHANGHAI, China, March 12, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today IND application of GB492 (IMSA101, Stimulator of interferon genes,STING) is under review by NMPA. The Phase I/IIa clinical trials will evaluate the safety and efficacy of GB492 as monotherapy and in combination with recombinant anti-human PD-1/L1 functional monoclonal antibody, in patients with advanced treatment-refractory malignancies.
11 Mar, 2021
SHANGHAI, China, March. 11, 2021 -- Genor Biopharma announced today that the preclinical progress of the company's leading preclinical drug candidates, GB261, GB262, GB263 and GB264 from its San-Francisco based bi-specific/tri-specific antibody platform, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The AACR annual meeting will be held between April 10th and April 15th and between May 17th and 21th online. Abstracts have been published on the AACR website.